Transcriptional response to interferon beta-1a treatment in patients with secondary progressive multiple sclerosis

BACKGROUND: Interferon (IFN) beta-1a is an approved treatment for relapsing remitting multiple sclerosis (RRMS) and has been examined for use in secondary progressive multiple sclerosis (SPMS). However, no information regarding blood transcriptional changes induced by IFN treatment in SPMS patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Gurevich, Michael, Miron, Gadi, Falb, Rina Zilkha, Magalashvili, David, Dolev, Mark, Stern, Yael, Achiron, Anat
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4654830/
https://www.ncbi.nlm.nih.gov/pubmed/26589141
http://dx.doi.org/10.1186/s12883-015-0495-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4654830/
https://www.ncbi.nlm.nih.gov/pubmed/26589141
http://dx.doi.org/10.1186/s12883-015-0495-x

Ejemplares similares